These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 19380191

  • 1. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY, Lee SW, Hong JP, Chang SE, Choe H, Choi J.
    Cancer Lett; 2009 Oct 08; 283(2):135-42. PubMed ID: 19380191
    [Abstract] [Full Text] [Related]

  • 2. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 3. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.
    Cancer Res; 2004 Aug 01; 64(15):5355-62. PubMed ID: 15289342
    [Abstract] [Full Text] [Related]

  • 4. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S.
    Cancer Chemother Pharmacol; 2006 Nov 01; 58(5):577-84. PubMed ID: 16532343
    [Abstract] [Full Text] [Related]

  • 5. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
    Johnson FM, Saigal B, Donato NJ.
    J Cell Physiol; 2005 Nov 01; 205(2):218-27. PubMed ID: 15887238
    [Abstract] [Full Text] [Related]

  • 6. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
    Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J.
    Cancer Res; 2001 Sep 01; 61(17):6500-10. PubMed ID: 11522647
    [Abstract] [Full Text] [Related]

  • 7. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
    Tanno S, Ohsaki Y, Nakanishi K, Toyoshima E, Kikuchi K.
    Oncol Rep; 2004 Nov 01; 12(5):1053-7. PubMed ID: 15492792
    [Abstract] [Full Text] [Related]

  • 8. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y, Li X, Jiang J, Frank SJ.
    Oncogene; 2006 Dec 07; 25(58):7565-76. PubMed ID: 16785991
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.
    Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL.
    Oncogene; 2002 Sep 12; 21(41):6255-63. PubMed ID: 12214266
    [Abstract] [Full Text] [Related]

  • 11. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
    Cunningham MP, Thomas H, Fan Z, Modjtahedi H.
    Cancer Res; 2006 Aug 01; 66(15):7708-15. PubMed ID: 16885373
    [Abstract] [Full Text] [Related]

  • 12. Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts.
    Kyriakakis E, Maslova K, Frachet A, Ferri N, Contini A, Pfaff D, Erne P, Resink TJ, Philippova M.
    Cell Signal; 2013 May 01; 25(5):1044-53. PubMed ID: 23411345
    [Abstract] [Full Text] [Related]

  • 13. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
    Festuccia C, Gravina GL, Millimaggi D, Muzi P, Speca S, Ricevuto E, Vicentini C, Bologna M.
    Oncol Rep; 2007 Aug 01; 18(2):503-11. PubMed ID: 17611677
    [Abstract] [Full Text] [Related]

  • 14. EGF-dependent and independent programmed cell death pathways in NCI-H596 nonsmall cell lung cancer cells.
    Lei W, Mayotte JE, Levitt ML.
    Biochem Biophys Res Commun; 1998 Apr 28; 245(3):939-45. PubMed ID: 9588219
    [Abstract] [Full Text] [Related]

  • 15. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Amin DN, Bielenberg DR, Lifshits E, Heymach JV, Klagsbrun M.
    Microvasc Res; 2008 May 28; 76(1):15-22. PubMed ID: 18440031
    [Abstract] [Full Text] [Related]

  • 16. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
    Normanno N, Campiglio M, Maiello MR, De Luca A, Mancino M, Gallo M, D'Alessio A, Menard S.
    Breast Cancer Res Treat; 2008 Nov 28; 112(1):25-33. PubMed ID: 18060492
    [Abstract] [Full Text] [Related]

  • 17. Phosphatase-mediated crosstalk control of ERK and p38 MAPK signaling in corneal epithelial cells.
    Wang Z, Yang H, Tachado SD, Capó-Aponte JE, Bildin VN, Koziel H, Reinach PS.
    Invest Ophthalmol Vis Sci; 2006 Dec 28; 47(12):5267-75. PubMed ID: 17122112
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
    Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA.
    J Natl Cancer Inst; 2005 Aug 17; 97(16):1185-94. PubMed ID: 16106023
    [Abstract] [Full Text] [Related]

  • 19. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A.
    Clin Cancer Res; 2006 Jan 15; 12(2):617-25. PubMed ID: 16428508
    [Abstract] [Full Text] [Related]

  • 20. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
    Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J.
    Clin Cancer Res; 2005 Mar 15; 11(6):2398-407. PubMed ID: 15788691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.